Research ExplorerPublicationsMidregional proadrenomedullin and its change predicts recurr...

Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study

Standard

Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. / Funke-Kaiser, Anne; Mann, Kristy; Colquhoun, David; Zeller, Tanja; Hunt, David; Simes, John; Sullivan, David; Sydow, Karsten; West, Malcolm; White, Harvey; Blankenberg, Stefan; Tonkin, Andrew M; LIPID Study Investigators.

In: INT J CARDIOL, Vol. 172, No. 2, 15.03.2014, p. 411-418.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Funke-Kaiser, A, Mann, K, Colquhoun, D, Zeller, T, Hunt, D, Simes, J, Sullivan, D, Sydow, K, West, M, White, H, Blankenberg, S, Tonkin, AM & LIPID Study Investigators 2014, 'Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study', INT J CARDIOL, vol. 172, no. 2, pp. 411-418. https://doi.org/10.1016/j.ijcard.2014.01.064

APA

Funke-Kaiser, A., Mann, K., Colquhoun, D., Zeller, T., Hunt, D., Simes, J., Sullivan, D., Sydow, K., West, M., White, H., Blankenberg, S., Tonkin, A. M., & LIPID Study Investigators (2014). Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. INT J CARDIOL, 172(2), 411-418. https://doi.org/10.1016/j.ijcard.2014.01.064

Vancouver

Funke-Kaiser A, Mann K, Colquhoun D, Zeller T, Hunt D, Simes J et al. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. INT J CARDIOL. 2014 Mar 15;172(2):411-418. https://doi.org/10.1016/j.ijcard.2014.01.064

Bibtex

@article{4fa91031f94648a6b8ac61ad16cd62a4,
title = "Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study",
abstract = "BACKGROUND: Biomarkers may contribute to risk stratification in coronary heart disease (CHD). We examined whether plasma midregional proadrenomedullin (MR-proADM) concentration at baseline and its change over one year predicts long-term outcomes in stable CHD patients.METHODS: The LIPID study randomised patients 3-36 months after an acute coronary syndrome with total cholesterol 4.0-7.0 mmol/L (155-271 mg/dL), to placebo or pravastatin 40 mg. Follow-up was 6.0 years. MR-proADM plasma concentrations at baseline and one year later were determined in 7863 and 6658 patients, respectively. These were categorised into quartiles to perform Cox regression analysis, adjusting for baseline parameters.RESULTS: Baseline MR-proADM concentrations predicted major CHD events (non-fatal myocardial infarction or CHD death; hazard ratio (HR) 1.52, 1.26-1.84 for Q4-Q1), CHD death (HR 2.21, 1.67-2.92), heart failure (HR 2.30, 1.78-2.97) and all-cause mortality (HR 1.82, 1.49-2.23). Associations were still significant after adjustment for baseline B-type natriuretic peptide (BNP) concentration. Increase in MR-proADM after one year was associated with increased risk of subsequent CHD events (HR 1.34, 1.08-1.66), non-fatal myocardial infarction (HR 1.50, 1.12-2.03), heart failure (HR 1.78, 1.37-2.30) and all-cause mortality (HR 1.31, 1.04-1.64). Associations with heart failure and all-cause mortality remained significant after adjusting for baseline and change in BNP concentration. Change in MR-proADM moderately improved risk reclassification for major CHD events (net reclassification improvement (NRI) 3.48%) but strongly improved risk reclassification for heart failure (NRI 5.60%).CONCLUSIONS: Baseline and change in MR-proADM concentrations over one year are associated with risk of major clinical events, even after adjustment for BNP concentrations.",
keywords = "Adrenomedullin/blood, Adult, Aged, Biomarkers/blood, Coronary Disease/blood, Female, Follow-Up Studies, Heart Failure/blood, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Male, Middle Aged, Natriuretic Peptide, Brain/blood, Pravastatin/therapeutic use, Predictive Value of Tests, Prognosis, Protein Precursors/blood, Recurrence, Risk Assessment",
author = "Anne Funke-Kaiser and Kristy Mann and David Colquhoun and Tanja Zeller and David Hunt and John Simes and David Sullivan and Karsten Sydow and Malcolm West and Harvey White and Stefan Blankenberg and Tonkin, {Andrew M} and {LIPID Study Investigators}",
note = "Copyright {\textcopyright} 2014 Elsevier Ireland Ltd. All rights reserved.",
year = "2014",
month = mar,
day = "15",
doi = "10.1016/j.ijcard.2014.01.064",
language = "English",
volume = "172",
pages = "411--418",
journal = "INT J CARDIOL",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study

AU - Funke-Kaiser, Anne

AU - Mann, Kristy

AU - Colquhoun, David

AU - Zeller, Tanja

AU - Hunt, David

AU - Simes, John

AU - Sullivan, David

AU - Sydow, Karsten

AU - West, Malcolm

AU - White, Harvey

AU - Blankenberg, Stefan

AU - Tonkin, Andrew M

AU - LIPID Study Investigators

N1 - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

PY - 2014/3/15

Y1 - 2014/3/15

N2 - BACKGROUND: Biomarkers may contribute to risk stratification in coronary heart disease (CHD). We examined whether plasma midregional proadrenomedullin (MR-proADM) concentration at baseline and its change over one year predicts long-term outcomes in stable CHD patients.METHODS: The LIPID study randomised patients 3-36 months after an acute coronary syndrome with total cholesterol 4.0-7.0 mmol/L (155-271 mg/dL), to placebo or pravastatin 40 mg. Follow-up was 6.0 years. MR-proADM plasma concentrations at baseline and one year later were determined in 7863 and 6658 patients, respectively. These were categorised into quartiles to perform Cox regression analysis, adjusting for baseline parameters.RESULTS: Baseline MR-proADM concentrations predicted major CHD events (non-fatal myocardial infarction or CHD death; hazard ratio (HR) 1.52, 1.26-1.84 for Q4-Q1), CHD death (HR 2.21, 1.67-2.92), heart failure (HR 2.30, 1.78-2.97) and all-cause mortality (HR 1.82, 1.49-2.23). Associations were still significant after adjustment for baseline B-type natriuretic peptide (BNP) concentration. Increase in MR-proADM after one year was associated with increased risk of subsequent CHD events (HR 1.34, 1.08-1.66), non-fatal myocardial infarction (HR 1.50, 1.12-2.03), heart failure (HR 1.78, 1.37-2.30) and all-cause mortality (HR 1.31, 1.04-1.64). Associations with heart failure and all-cause mortality remained significant after adjusting for baseline and change in BNP concentration. Change in MR-proADM moderately improved risk reclassification for major CHD events (net reclassification improvement (NRI) 3.48%) but strongly improved risk reclassification for heart failure (NRI 5.60%).CONCLUSIONS: Baseline and change in MR-proADM concentrations over one year are associated with risk of major clinical events, even after adjustment for BNP concentrations.

AB - BACKGROUND: Biomarkers may contribute to risk stratification in coronary heart disease (CHD). We examined whether plasma midregional proadrenomedullin (MR-proADM) concentration at baseline and its change over one year predicts long-term outcomes in stable CHD patients.METHODS: The LIPID study randomised patients 3-36 months after an acute coronary syndrome with total cholesterol 4.0-7.0 mmol/L (155-271 mg/dL), to placebo or pravastatin 40 mg. Follow-up was 6.0 years. MR-proADM plasma concentrations at baseline and one year later were determined in 7863 and 6658 patients, respectively. These were categorised into quartiles to perform Cox regression analysis, adjusting for baseline parameters.RESULTS: Baseline MR-proADM concentrations predicted major CHD events (non-fatal myocardial infarction or CHD death; hazard ratio (HR) 1.52, 1.26-1.84 for Q4-Q1), CHD death (HR 2.21, 1.67-2.92), heart failure (HR 2.30, 1.78-2.97) and all-cause mortality (HR 1.82, 1.49-2.23). Associations were still significant after adjustment for baseline B-type natriuretic peptide (BNP) concentration. Increase in MR-proADM after one year was associated with increased risk of subsequent CHD events (HR 1.34, 1.08-1.66), non-fatal myocardial infarction (HR 1.50, 1.12-2.03), heart failure (HR 1.78, 1.37-2.30) and all-cause mortality (HR 1.31, 1.04-1.64). Associations with heart failure and all-cause mortality remained significant after adjusting for baseline and change in BNP concentration. Change in MR-proADM moderately improved risk reclassification for major CHD events (net reclassification improvement (NRI) 3.48%) but strongly improved risk reclassification for heart failure (NRI 5.60%).CONCLUSIONS: Baseline and change in MR-proADM concentrations over one year are associated with risk of major clinical events, even after adjustment for BNP concentrations.

KW - Adrenomedullin/blood

KW - Adult

KW - Aged

KW - Biomarkers/blood

KW - Coronary Disease/blood

KW - Female

KW - Follow-Up Studies

KW - Heart Failure/blood

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain/blood

KW - Pravastatin/therapeutic use

KW - Predictive Value of Tests

KW - Prognosis

KW - Protein Precursors/blood

KW - Recurrence

KW - Risk Assessment

U2 - 10.1016/j.ijcard.2014.01.064

DO - 10.1016/j.ijcard.2014.01.064

M3 - SCORING: Journal article

C2 - 24508492

VL - 172

SP - 411

EP - 418

JO - INT J CARDIOL

JF - INT J CARDIOL

SN - 0167-5273

IS - 2

ER -